Skip to content

Trial Summary

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

Acronym:

daNIS-2

ACTRN/NCT /ethics:

NCT04935359

Scientific title:

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Sponsor / Cooperative group:

Novartis Pharmaceuticals

Trial & Patient Characteristics

Cancer TypePancreatic Ductal Adenocarcinoma
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2021-09-30
Anticipated End Date2026-01-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Emailadmin@cancerresearchsa.com.au
Phone08 8359 2565
Principal InvestigatorA/Prof Rohit Joshi
Recruitment StatusRecruiting